Home › Research › Down syndrome and Alzheimer's
Novel predictors of Alzheimer's disease in Down syndrome identified using machine learning
Rubenstein E, Tewolde S, Michals A, Fortea J, Jimenez MP, Skotko BG, Tripodis Y, Weuve J et al.. Journal of Alzheimer's disease : JAD, 2025-10-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BackgroundMost adults with Down syndrome will develop Alzheimer's disease (AD) due to the triplication of the amyloid precursor protein in the 21 st chromosome. Predictors of condition onset are less known.ObjectiveWe used Medicaid and Medicare data and machine learning to identify which co-occurring conditions predict incident AD in United States adults with Down syndrome.MethodsWe examined adults with Down syndrome enrolled in Medicaid and/or Medicare between 2011 and 2019. We identified AD and other conditions using ICD 9 and 10 codes. We used a case-control design with risk set sampling to have that controls to mimic the distribution of times of incident AD. We trained gradient boosted trees to identify strongest predictors.ResultsThe cohort had a mean age at entry of 44.6 years, 46.2% were male, and 73.7% were white non-Hispanic. 16,398 had incident AD diagnoses over the study period. The machine learning model had an area under the curve of 0.86 and high positive predictive value. Strongest predictors of increased probability of AD were age, dual Medicaid/Medicare enrollment; incident epilepsy or incident ulcer three years before index date; any hypothyroidism, schizophrenia, or hyperlipidemia. We found synergistic interaction between epilepsy and enrollment by age.ConclusionsPredictors aligned with known predictors in the general population and characteristics that signal AD symptom onset. New onset epilepsy may be a relevant clinical sign. Identifying these predictors highlights areas for further etiologic inquiry and intervention.
What this study adds
Evidence grade: Moderate
This is a case-control study. Using Medicaid and Medicare data and machine learning, this case-control study identified age, dual enrollment, incident epilepsy or ulcer, hypothyroidism, schizophrenia and hyperlipidemia as predictors of Alzheimer's disease diagnosis in adults with Down syndrome. Reported effect size: 46.2%; 73.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rubenstein, E., Tewolde, S., Michals, A., Fortea, J., Jimenez, M. P., Skotko, B. G., et al. (2025). Novel predictors of Alzheimer's disease in Down syndrome identified using machine learning. Journal of Alzheimer's disease : JAD. https://doi.org/10.1177/13872877251385423
Vancouver
Rubenstein E, Tewolde S, Michals A, Fortea J, Jimenez MP, Skotko BG, et al. Novel predictors of Alzheimer's disease in Down syndrome identified using machine learning. Journal of Alzheimer's disease : JAD. 2025. doi:10.1177/13872877251385423. PMID: 41105592.
BibTeX
@article{rubenstein2025-41105592,
author = {Rubenstein, E. and Tewolde, S. and Michals, A. and Fortea, J. and Jimenez, M. P. and Skotko, B. G. and Tripodis, Y. and Weuve, J. and others},
title = {{Novel predictors of Alzheimer's disease in Down syndrome identified using machine learning}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2025},
doi = {10.1177/13872877251385423},
pmid = {41105592},
url = {https://doi.org/10.1177/13872877251385423}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We found synergistic interaction between epilepsy and enrollment by age.ConclusionsPredictors aligned with known predictors in the general population and characteristics that signal AD symptom onset.
Why it matters
Using Medicaid and Medicare data and machine learning, this case-control study identified age, dual enrollment, incident epilepsy or ulcer, hypothyroidism, schizophrenia and hyperlipidemia as predictors of Alzheimer's disease diagnosis in adults with Down syndrome. These are risk associations for prediction, not evidence of a treatment, cure or prevention.
Study details
- Study designcase-control study
- Effect size46.2%; 73.7%
- Evidence strengthModerate
How this study scored 45/100
Published in a peer-reviewed journal, and it is a case-control study. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Anthony J. Rosellini: h-index 32 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Massachusetts General Hospital: institution h-index 2,057 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41105592) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.